TrialRandomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis
Trial details
- Registry ID
- NCT01613118
- Phase
- Phase 2
TVTX
Travere Therapeutics, Inc.
Company identity checked against sources
Browse linked trials and recorded changes, or follow this company for updates.
7Trials in this database
6Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far
Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.
Completion dates · Pro
Which trial dates moved later?
Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features
Included trials
Check company identity sourceStudy of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS)
Trial details
- Registry ID
- NCT03493685
- Phase
- Phase 3
A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy
Trial details
- Registry ID
- NCT03762850
- Phase
- Phase 3
Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
Trial details
- Registry ID
- NCT05003986
- Phase
- Phase 2
A Study to Investigate Safety and Effect of Sparsentan in Combination With SGLT2 Inhibition in Participants With IgAN
Trial details
- Registry ID
- NCT05856760
- Phase
- Phase 2
A Study to Investigate Efficacy and Safety of Pegtibatinase Compared With Placebo in Participants ≥12 to ≤65 Years of Age With Classical Homocystinuria (HCU) Due to Cystathionine Beta Synthase Deficiency Receiving Standard of Care Treatment
Trial details
- Registry ID
- NCT06247085
- Phase
- Phase 3
A Long-term Extension Study to Assess the Long-term Safety and Efficacy of Pegtibatinase Treatment in Participants ≥5 to ≤65 Years of Age With Classical Homocystinuria (HCU) (ENSEMBLE)
Trial details
- Registry ID
- NCT06431893
- Phase
- Phase 3
Latest recorded trial changes
A Long-term Extension Study to Assess the Long-term Safety and Efficacy of Pegtibatinase Treatment in Participants ≥5 to ≤65 Years of Age With Classical Homocystinuria (HCU) (ENSEMBLE)
NCT06431893 · Travere Therapeutics, Inc.
Primary completion date
Recorded edit− Previous value
2027-01
+ Updated value
2030-08
A Study to Investigate Efficacy and Safety of Pegtibatinase Compared With Placebo in Participants ≥12 to ≤65 Years of Age With Classical Homocystinuria (HCU) Due to Cystathionine Beta Synthase Deficiency Receiving Standard of Care Treatment
NCT06247085 · Travere Therapeutics, Inc.
Primary outcomes · main study measures
Text edit · unverified significance− Previous value
measure: Change from baseline in plasma tHcy levels
+ Updated value
measure: Change from baseline in plasma tHcy levels - Weeks 6 to 12
The saved outcome text may be shortened. Check the source for full wording.
Primary completion date
Recorded edit− Previous value
2025-12
+ Updated value
2027-08
Recruitment status
Recorded edit− Previous value
Active not recruiting
+ Updated value
Recruiting
Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS)
NCT03493685 · Travere Therapeutics, Inc.
Recruitment status
Recorded edit− Previous value
Active not recruiting
+ Updated value
Completed
A Study to Investigate Safety and Effect of Sparsentan in Combination With SGLT2 Inhibition in Participants With IgAN
NCT05856760 · Travere Therapeutics, Inc.
Primary outcomes · main study measures
Text edit · unverified significance− Previous value
measure: Change in urine albumin-creatinine ratio (UA/C) at Week 24
+ Updated value
measure: Change in Urine Albumin-creatinine Ratio (UA/C) at Week 24
The saved outcome text may be shortened. Check the source for full wording.